Pay in 4 interest-free payments of $7.48 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
The 24.2% mean reduction at 12mg over 48 weeks exceeded the results seen with both semaglutide and tirzepatide in their respective trials
Frhlich, A
The long-acting GLP-1 agonist segment dominated the market in 2025 owing to its superior dosing convenience, improved patient observation, and sustained therapeutic efficacy
The darker you are, the more radical the results
Semaglutide and newer GLP-1s are more powerful but come with a higher chance of side effects and a steeper price tag
US$ 24.56
US$ 24.26
US$ 20.47
US$ 20.49
US$ 24.79
US$ 28.81
US$ 23.69
![Scathing Seminary [Foil] [MRC] Preorder September](https://cdn.shopify.com/s/files/1/0523/3501/8158/files/634577_400w_a1f834ab-6c7c-4639-9e13-3caf739c83b3.jpg?v=1751380285)
